 |
|
|
| |
SVR and pharmacokinetics of the HCV protease inhibitor BI 201335 with PegIFN/RBV in HCV genotype-1 patients with compensated liver cirrhosis and non-response to previous PegIFN/RBV
|
| |
| |
Reported by Jules Levin
AASLD Nov 5-8 2011 SF
Stanislas Pol,1 Thomas Berg,2 Maurizio Bonacini,3 Marcus Schuchmann,4 Jacob Lalezari,5 Andreas Erhardt,6 Marc Bourliere,7 Michael Manns,8 Jerry Stern,9 Gerd Steinmann,10 Chan-Loi Yong,9 Joe Scherer,9 Wulf O. Boecher10
1Hopital Cochin, Paris, France; 2Charite, Campus Virchow-Klinikum, Berlin, Germany; 3CPMC Research Institute, San Francisco, CA, USA; 4Internal Medicine 1, University Hospital Mainz, Germany; 5Quest Clinical Research, San Francisco, CA, USA; 6Internal Medicine, University Hospital Duesseldorf, Germany; 7Hopital Saint Joseph, Marseilles, France; 8Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany; 9Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA; 10Boehringer Ingelheim Pharma GmbH, Biberach, Germany
|
| |
|
|
|
|
|
